A recent study conducted by King’s College London revealed that the natural psychedelic compound in magic mushrooms may effectively alleviate treatment-resistant depression. The trial, published in Nature Medicine, involved 60 individuals with depression resistant to conventional treatments. After three weeks of receiving 25mg of psilocybin, over 40% of patients experienced remission of symptoms. The study, funded publicly and conducted at South London and Maudsley NHS Foundation Trust, witnessed a significant number of patients achieving remission, no longer meeting clinical criteria.
Results indicated that 56% of participants showed improvement after six weeks, compared to only 3% in the placebo group. Professor James Rucker, from King’s College London, and a consultant psychiatrist at the NHS Foundation Trust, emphasized the feasibility of the trial design in individuals with treatment-resistant depression. He highlighted the positive response to psilocybin compared to a placebo, underscoring the importance of publicly funded clinical trials in evaluating new interventions.
One participant shared their intense emotional experience during the trial, expressing a deep emotional release and newfound understanding of their depression. Recruitment for the trial initially took place at a research facility before transitioning to a community mental health setting. Catherine Bird, a senior clinical trials manager, noted the safe administration of psilocybin outside hospital wards, emphasizing the need for a calm environment and trained staff rather than medical monitoring.
Prof Rucker advocated for larger publicly funded trials of psilocybin therapy in community settings, highlighting their convenience and reduced anxiety for patients compared to hospital settings. The study’s findings suggest promising prospects for psilocybin therapy in treating depression.
